Moreover, the microenvironment of TP53-mutant myelodysplastic syndromes (MDS) has been shown to possess immune-dominant and immune-evasive phenotypes, which may provide better therapeutic effects for patients with such TP53 mutations. The gene discussed is TP53; the disease is myelodysplastic syndrome.